I’ve read with interest a number of recent publications that suggest that cognitive behavioural therapy (CBT) may be less effective in patients receiving disability benefits versus other patients. The theory here is that the specific circumstances of being on disability benefits may somehow lead to poorer outcomes following CBT. There’s some evidence in other clinical [read the full story…]
The CoBalT trial was published last week in the Lancet. This important randomised controlled trial (RCT) examined the effectiveness of cognitive behavioural therapy (CBT) as an add-on treatment to usual care for people with treatment resistant depression. Previous studies have shown that only around one third of people with depression respond well to treatment with [read the full story…]
Much of the research about depression in children and adolescents focuses on how to treat the illness during the acute phase. This review from the Cochrane Depression, Anxiety and Neurosis Review Group is more concerned with the ways in which interventions can be used to prevent relapse or recurrence of depressive disorders. The review looks specifically at two [read the full story…]
The stigma and shame associated with mental illness can prevent people from seeking help. This can lead to much poorer outcomes as patients may often miss out on vital treatment early on in their illness. A number of theories have been put forward to explain why certain groups (e.g. young people, men, refugees) seem less [read the full story…]
A great deal of time and money has been spent on improving the diagnosis and management of depression and self-harm in primary care. The evidence tells us that collaborative care and case management can be effective approaches, which is all well and good, but these complex interventions are not always feasible. This new cluster randomised [read the full story…]
Research has shown that antidepressant use can lead to a non-significant increase in the risk of suicidal thoughts and behaviour in people aged under 25 (Stone et al, BMJ 2009). This subject rightly received a large amount of media coverage a few years ago and it remains an area where new studies can add to [read the full story…]
There are many different antidepressants to choose from when treating acute depression, so it’s always helpful to see a systematic review that looks at the efficacy, acceptability and tolerability of the different drugs. This new Cochrane review compares duloxetine hydrochloride (one of the newer drugs) with other antidepressants and finds little high quality evidence upon [read the full story…]
A new cross-sectional survey published in The Lancet has revealed some unsurprising but nonetheless sobering facts about how people with depression are stigmatised. The research team, funded by money from the European Commission, interviewed 1,082 people with depression from 35 countries across the world. They used the discrimination and stigma scale (version 12; DISC-12) to [read the full story…]
There has been a lot of discussion over recent years about the ways in which genetic testing may help make the treatment of depression become more targeted and effective. The theory is that genetic markers may help predict how different people are likely to respond to different drugs. This is clearly something that would interest [read the full story…]
The new batch of Cochrane systematic reviews are published today and there are a couple of important new mental health reviews that I’ll be blogging about over the next few days. First comes a piece of research looking at the effectiveness of collaborative care for patients with depression or anxiety. Collaborative care involves a range [read the full story…]
